(A Little) Clarity on Convalescent Plasma for Covid-19.
作者信息
Katz Louis M
机构信息
From the Mississippi Valley Regional Blood Center, Davenport, IA.
出版信息
N Engl J Med. 2021 Feb 18;384(7):666-668. doi: 10.1056/NEJMe2035678. Epub 2021 Jan 13.
Abstract
摘要
相似文献
1
(A Little) Clarity on Convalescent Plasma for Covid-19.关于新冠康复期血浆治疗的一点解读
N Engl J Med. 2021 Feb 18;384(7):666-668. doi: 10.1056/NEJMe2035678. Epub 2021 Jan 13.
2
Convalescent plasma for COVID-19 considerations.关于新冠病毒病恢复期血浆的考量
Transfus Apher Sci. 2021 Feb;60(1):102927. doi: 10.1016/j.transci.2020.102927. Epub 2020 Aug 27.
3
Covid-19 convalescent plasma and SARS-CoV-2 viral variants.新冠康复者血浆与严重急性呼吸综合征冠状病毒2病毒变体
Transfus Clin Biol. 2021 Aug;28(3):306. doi: 10.1016/j.tracli.2021.05.008. Epub 2021 May 29.
4
Use of Convalescent Plasma in the Management of COVID-19.康复期血浆在新型冠状病毒肺炎治疗中的应用
Mo Med. 2021 Mar-Apr;118(2):118.
5
Implications of Coronavirus Disease 2019 (COVID-19) Antibody Dynamics for Immunity and Convalescent Plasma Therapy.2019年冠状病毒病（COVID-19）抗体动力学对免疫及恢复期血浆治疗的影响
Clin Infect Dis. 2021 Aug 2;73(3):e540-e542. doi: 10.1093/cid/ciaa1213.
6
[COVID-19: blood sufficiency versus convalescent plasma?].[新冠病毒肺炎：血液充足疗法与康复期血浆疗法？]
Rev Med Chil. 2020 Jun;148(6):721-723. doi: 10.4067/S0034-98872020000600721.
7
Appropriate selection of convalescent plasma donors for COVID-19.为新冠病毒病（COVID-19）康复者血浆捐献者进行恰当选择。
Lancet Infect Dis. 2021 Feb;21(2):168-169. doi: 10.1016/S1473-3099(20)30470-9. Epub 2020 Jun 15.
8
How Safe Is COVID-19 Convalescent Plasma?新冠康复者血浆有多安全？
Mayo Clin Proc. 2021 Aug;96(8):2279-2281. doi: 10.1016/j.mayocp.2021.06.011. Epub 2021 Jun 25.
9
Correspondence on 'CONVALESCENT plasma for COVID-19'.关于“COVID-19康复期血浆治疗”的通信
Eur J Clin Invest. 2021 Nov;51(11):e13677. doi: 10.1111/eci.13677. Epub 2021 Sep 13.
10
Convalescent plasma therapy in patients with COVID-19.新型冠状病毒肺炎患者的恢复期血浆治疗
Transfus Apher Sci. 2021 Feb;60(1):103017. doi: 10.1016/j.transci.2020.103017. Epub 2020 Nov 19.
引用本文的文献
1
Immunogenic Potential of Selected Peptides from SARS-CoV-2 Proteins and Their Ability to Block S1/ACE-2 Binding.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）蛋白中选定肽段的免疫原性潜力及其阻断S1/血管紧张素转换酶2（ACE-2）结合的能力
Viruses. 2025 Jan 24;17(2):165. doi: 10.3390/v17020165.
2
Clinical Course and Factors Associated With Hospital Admission and Mortality among Sars-Cov 2 Patients within Nairobi Metropolitan Area.内罗毕大都市区2019冠状病毒病患者的临床病程以及与住院和死亡相关的因素
medRxiv. 2024 May 15:2024.05.15.24307403. doi: 10.1101/2024.05.15.24307403.
3
Clinical Utility of SARS-CoV-2 Serological Testing and Defining a Correlate of Protection.新型冠状病毒2型血清学检测的临床应用及确定保护相关性
Vaccines (Basel). 2023 Oct 26;11(11):1644. doi: 10.3390/vaccines11111644.
4
COVID-19: An Overview of SARS-CoV-2 Variants-The Current Vaccines and Drug Development.新型冠状病毒肺炎（COVID-19）：严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）变异株概述——当前疫苗和药物研发进展。
Biomed Res Int. 2023 Aug 29;2023:1879554. doi: 10.1155/2023/1879554. eCollection 2023.
5
Antiviral Treatment of Coronavirus Disease-2019 Pneumonia.新型冠状病毒肺炎抗病毒治疗。
Clin Chest Med. 2023 Jun;44(2):279-297. doi: 10.1016/j.ccm.2022.11.008. Epub 2022 Nov 28.
6
Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications.中和抗体对 SARS-CoV-2 感染的保护作用和保护机制及其潜在的临床意义。
Front Immunol. 2023 Jan 19;14:1055457. doi: 10.3389/fimmu.2023.1055457. eCollection 2023.
7
Pharmacokinetic and Pharmacodynamic Effects of Polyclonal Antibodies against SARS-CoV2 in Mice.多克隆抗体对 SARS-CoV2 在小鼠中的药代动力学和药效学影响。
Viruses. 2022 Dec 30;15(1):123. doi: 10.3390/v15010123.
8
Efficacy of COVID-HIGIV in animal models of SARS-CoV-2 infection.COVID-HIGIV 在 SARS-CoV-2 感染动物模型中的疗效。
Sci Rep. 2022 Oct 10;12(1):16956. doi: 10.1038/s41598-022-21223-2.
9
Convalescent Plasma for COVID-19: A Single Center Prospective Experience with Serial Antibody Measurements and Review of the Literature.新冠康复期血浆治疗：单中心连续抗体检测的前瞻性经验及文献综述
Pathogens. 2022 Aug 23;11(9):958. doi: 10.3390/pathogens11090958.
10
COVID-19 in Missouri 2020-2021: A Perspective on Origins, Spread & Controversies, Part I.2020 - 2021年密苏里州的新冠疫情：关于起源、传播及争议的观点，第一部分
Mo Med. 2022 Mar-Apr;119(2):98-105.
本文引用的文献
1
Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19.恢复期血浆抗体水平与新冠死亡风险。
N Engl J Med. 2021 Mar 18;384(11):1015-1027. doi: 10.1056/NEJMoa2031893. Epub 2021 Jan 13.
2
Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults.早期高滴度血浆疗法预防老年人重症 COVID-19。
N Engl J Med. 2021 Feb 18;384(7):610-618. doi: 10.1056/NEJMoa2033700. Epub 2021 Jan 6.
3
A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia.新冠肺炎重症肺炎患者恢复期血浆的随机临床试验。
N Engl J Med. 2021 Feb 18;384(7):619-629. doi: 10.1056/NEJMoa2031304. Epub 2020 Nov 24.
4
5
Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality.使用恢复期血浆治疗 2019 年冠状病毒病患者显示出死亡率显著降低的信号。
Am J Pathol. 2020 Nov;190(11):2290-2303. doi: 10.1016/j.ajpath.2020.08.001. Epub 2020 Aug 11.
6
Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial.恢复期血浆疗法对重症和危及生命的 COVID-19 患者临床改善时间的影响：一项随机临床试验。
JAMA. 2020 Aug 4;324(5):460-470. doi: 10.1001/jama.2020.10044.
7
Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial.抗流感免疫血浆治疗重症甲型流感患者的随机、双盲、3 期临床试验。
Lancet Respir Med. 2019 Nov;7(11):941-950. doi: 10.1016/S2213-2600(19)30199-7. Epub 2019 Sep 30.
8
The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis.恢复期血浆和高效免疫球蛋白治疗病毒性病因严重急性呼吸道感染的有效性：系统评价与探索性Meta分析
J Infect Dis. 2015 Jan 1;211(1):80-90. doi: 10.1093/infdis/jiu396. Epub 2014 Jul 16.
9
Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?荟萃分析：用于西班牙流感肺炎的恢复期血液制品：未来治疗H5N1的方法？
Ann Intern Med. 2006 Oct 17;145(8):599-609. doi: 10.7326/0003-4819-145-8-200610170-00139. Epub 2006 Aug 29.
Zotero 插件